DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye

Core Insights - DiagnosTear Technologies Inc. announced promising interim results from its multi-center clinical study in Israel for the TeaRx™ Red Eye diagnostic platform, aimed at improving ocular diagnostics [1][6] Company Overview - DiagnosTear Technologies Inc. is a leader in rapid, point-of-care diagnostics for ocular diseases, focusing on multi-parametric tests that provide actionable insights based on tear-fluid analysis [8] Product Development - The TeaRx™ Red Eye device is designed to differentiate between three types of red eye conditions: Adenoviral conjunctivitis, Herpetic keratitis, and Allergic conjunctivitis, which collectively lead to millions of clinic visits annually [2][6] - The device addresses the current lack of rapid diagnostics, which contributes to misdiagnosis and inappropriate treatments [2] Clinical Study Details - The Israeli clinical program began in October 2023 and involves multiple leading health facilities, enrolling patients with suspected red eye conditions [3] - The study has recruited 130 subjects, with 66 samples evaluated for adenovirus, 60 for HSV-1/2, and 61 for total tear IgE [5] Interim Results - The TeaRx™ Red Eye assay showed high agreement rates: 92% positive and 100% negative for Adenovirus, 100% for HSV-1/2, and 73% positive and 93% negative for total tear IgE compared to reference methods [5] - These results indicate the device's reliability in identifying viral causes of red eye, which can lead to better point-of-care decisions [5][6] Future Plans - The Israeli study is expected to conclude by Q2 2026, with additional clinical programs in India and France also targeting completion by the same timeframe [6] - The company aims to compile a comprehensive dataset from these studies to support regulatory submissions and global commercialization of the TeaRx™ Red Eye [7]